Exact Sciences Corporation EXAS is likely to grow in the coming quarters, led by the broad-based momentum in Cologuard adoption. The company plans to transform cancer care by providing patients with valuable insights at every step of their diagnosis and treatment. 328 employees scalping strategy have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company’s employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
«Short-term momentum is flushed and crude [oil] is into some support in the low-$80s – we’d expect relief soon. The more troubling chart is likely the gasoline futures, which have broken down,» Verrone said. «We think the recent pullback in the shares presents an attractive buying opportunity for the stable, defensive retail stock,» analyst Steven Zaccone wrote in a Thursday note. «Our target multiple is also at a slight premium to the market share leaders retail basket given the recession-resistant aspect of ORLY’s business and consistent margin execution.» The new products include an international ETF (BINV) and two U.S. value funds (BSMC, BUSA).
Per the August Update, Exact Sciences’ management stated that its pipeline teams are focused on two of the most significant opportunities in cancer diagnostics, molecular residual disease and multi-cancer early detection. The company is working with Broad Institute to enhance and extend its molecular residual disease platform, Oncodetect. Further, EXAS announced the selection of its testing laboratory in Phoenix, AZ, for ComboMATCH clinical trials.
The Labor Department said claims came in at 207,000, slightly below a Dow Jones estimate of 210,000. Crude oil prices are on pace to see their biggest weekly losses since March. After falling to the $2.30 a gallon area on Wednesday, November RBOB gasoline futures took another leg down Thursday, sliding to $2.1789 — the lowest since late December, 2022. Consumer staples stocks lagged on Thursday, dragging down the S&P 500 sector 1.4%. Goldman is serving as a tech platform on these funds and is not involved in investment decisions. The ETF Accelerator is also named in the prospectus for the first ETF from Jeremy Grantham’s GMO, which was filed in August and has not launched yet.
An indication of interest to purchase securities involves no obligation or commitment of any kind. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before what is ufx forex broker making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. Haemonetics has an estimated earnings growth rate of 26.1% for fiscal 2024 compared with the industry’s 18.7%.
Secrets to Quick Profits this Earnings Season
The Zacks Consensus Estimate for 2023 revenues is pegged at $2.46 billion, suggesting an 18.1% rise from the 2022 reported number. In the past year, this Zacks Rank #3 (Hold) stock has surged 109% against a 12.4% decline of the industry and a 21.5% rise of the S&P 500 composite. Meanwhile, heavy dependence on the Cologuard test and operating in a highly competitive space are concerning for the company. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Merit Medical has gained 13.7% against the industry’s 8.7% decline in the past year. Boston Scientific has gained 6.8% against the industry’s 42.6% decline in the past year.
- Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million, an increase of 19%, and $617 million …
- In the last reported quarter, it delivered an average earnings surprise of 9.9%.
- Analyst Steven Alexopoulos upgraded the stock to overweight from neutral and maintained his price target.
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer. Get this delivered to your inbox, and more info about our products and services. The S&P Global Hong Kong SAR Purchasing Manager’s Index fell to 49.6 in September from 49.8 in August, partly hit by Typhoon Saola early last month. Hong Kong’s private sector contracted for the third consecutive month in September, according to PMI data from S&P Global. To be sure, that’s an increase of 2,000 claims from the week before. The latest initial jobless claims roughly matched economist expectations.
The new group was created last year to help Goldman’s large clients quickly bring their strategies and ideas to the ETF market. Brandes Investment Partners is the latest firm to join the growing ETF market, launching three funds on Thursday. Orchard Therapeutics — Shares nearly doubled understanding moving average indicators after Japanese pharmaceutical company Kyowa Kirin announced plans to acquire the biotechnology firm, which specializes in gene therapy, for $478 million. Everyday investors added $1.3 billion in cash equities over the last week, particularly buying into ETFs, according to JPMorgan.
Buy Exact Sciences (EXAS) Stock
MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%. Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.3%. BSX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 1.9%. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.
Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat’s FREE daily newsletter. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
How do I buy Exact Sciences (EXAS) stock?
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI. Rivian — Shares of the electric vehicle maker plunged 8.7% after Rivian announced a $1.5 billion convertible bond sale and issued disappointing guidance for the third quarter. The company said it expects between $1.29 billion and $1.31 billion in revenue, while analysts polled by StreetAccount forecast $1.31 billion.
Company Summary
There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Reports record results, raises full-year guidance, accelerates path to positive free cash flow First quarter highlights Total first quarter revenue of $602 million, an increase of 24%, and $598 milli… Exact Sciences said on Tuesday its next-generation screening test for colon cancer showed 30% lower false positive rate for detecting the disease in a study when compared to trial data on its already … Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million, an increase of 19%, and $617 million … Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
Exact Sciences’ approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program anal… © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Exact Sciences’ stock is owned by many different retail and institutional investors.
Energy, utilities post large declines this week
Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. You can find your newly purchased EXAS stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. Futures for West Texas Intermediate crude fell 5.61% to settle at $84.22 a barrel on Wednesday.
Nonetheless, the broad market index and the 30-stock Dow are on pace for a losing week. The Dow is down 1.16% week to date, and turned negative for the year during Tuesday’s selloff. The S&P 500 is lower by 0.7% for the week, while the Nasdaq is about flat. Stocks got a slight boost on Wednesday after the latest payroll data from ADP signaled to investors that the labor market is beginning to loosen. Ladner is optimistic that the labor market is softening with respect to the latest jobless claims and private payrolls data. Consumer staples companies led the broad market index’s losses Thursday.
The automaker also said that the cash and cash-like assets on its balance sheet decreased to $9.1 billion from $10.2 billion over the prior three months. Dragging down energy are major oil and gas companies such as Exxon Mobil, Phillips 66 and Devon Energy. Last week, the social media giant announced a slew of new artificial intelligence tools and digital assistants endorsed by celebrities like Paris Hilton and Kendall Jenner. Some better-ranked stocks in the broader medical space are Haemonetics HAE, Align Technology ALGN and Quanterix QTRX.
«I think that this market remains stronger than this selling action would have us believe at the moment,» Croft added. Check out some of the companies making headlines in premarket trading. Evercore ISI is bullish Nvidia, the best-performing S&P 500 stock this year, as the latest earnings season approaches. Analyst Steven Alexopoulos upgraded the stock to overweight from neutral and maintained his price target. A higher-for-longer rate environment could signal a rough patch ahead for the housing market, according to Bank of America. The funds are also notable because they are the first to come out of Goldman Sachs ETF Accelerator.